| Overview |
| bs-13614R-Cy5 |
| MYCBPAP Polyclonal Antibody, Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MYCBPAP |
| 401-500/947 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| AMAM-1; AMAP-1; AMAP1; AMY-1-binding protein 1; DKFZp434N1415; MYBPP_HUMAN; MYCBP-associated protein; Mycbpap. |
| AMAP-1 (AMY-1-binding protein 1), also known as AMAM-1 or MYCBPAP (MYCBP associated protein), is a 947 amino acid protein that is expressed specifically in testis and is involved in spermatogenesis and synaptic processes. AMAP-1 colocalizes with MYCBP (AMY-1) in cytoplasm and also localizes to membrane. The gene encoding AMAP-1 maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz